Exelixis   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (1994)

Organization Overview

First Clinical Trial
2004
NCT00086528
First Marketed Drug
2012
cabozantinib (cometriq)
First NDA Approval
2012
cabozantinib (cometriq)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Exelisis | Exelixis | EXELIXIS | EXELIXIS INC | Exelixis, Inc. (Study Sponsor)